PPMD Community

Webinar: PF-06252616 (Anti-Myostatin) - Scientific Rationale and Phase 2 Clinical Trial Design

Event Details

Webinar: PF-06252616 (Anti-Myostatin) - Scientific Rationale and Phase 2 Clinical Trial Design

Time: June 3, 2015 from 1pm to 2pm
Location: Online Webinar - Eastern Time Zone
Website or Map: http://www.readytalk.com/
Phone: 866.740.1260 -- Access code: 9449985
Event Type: webinar
Organized By: PPMD
Latest Activity: Jun 3, 2015

Export to Outlook or iCal (.ics)

Event Description

Wednesday, June 3, 2015 from 1pm to 2pm EDT

The webinar will provide an overview of Pfizer’s approach to advancing the science of an anti-myostatin monoclonal antibody as an investigational compound for potential therapeutic use in muscle wasting diseases, such as Duchenne muscular dystrophy. Dr. Michael Binks, VP and Head of Clinical Research for Pfizer’s Rare Disease Research Unit, will give a presentation and answer questions that have been submitted.

Questions:

Please submit questions in advance to info@parentprojectmd.org (subject line: Pfizer Webinar) by Monday, 6/1 at noon eastern.

Speakers:

  • Dr. Michael Binks, VP and Head of Clinical Research for Pfizer’s Rare Disease Research Unit

To Participate:

  1. Visit ReadyTalk.com and use participant code 9449985. (Be sure to test your computer beforehand)
  2. Audio Dial-In Information:
    • U.S. & Canada: Dial 866.740.1260 and use the Access Code 9449985
    • Outside the U.S. and Canada: Lookup your number

Comment Wall

Comment

RSVP for Webinar: PF-06252616 (Anti-Myostatin) - Scientific Rationale and Phase 2 Clinical Trial Design to add comments!

Join PPMD Community

Attending (4)

Might attend (1)

© 2017   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service